Find → Understand → Decide
Nab-paclitaxel
Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): efficacy failure; recruitment/execution failure; safety failure; strategic reprioritization; supply failure
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: MIXED
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-09-09 · trial:NCT05685602
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Drug Supply Issues
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: supply failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "2abab1ae5ed12947c201597d94a64d594786fb083f0029239d48b9916de773f2",
"metadata": {
"complete": false,
"content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"failed": false,
"last_checked": 1790026985.182528,
"last_success": 1790026985.182528,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
"raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT05685602"
}2026-09-10 · trial:NCT04251533
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: safety failure; recruitment/execution failure; strategic reprioritization · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "fd4c0acda90cac46e5c5b0b95e83a994893ac5ddf5205e3e2f95ff6c21a2d053",
"metadata": {
"complete": false,
"content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"failed": false,
"last_checked": 1790026980.9308648,
"last_success": 1790026980.9308648,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT04251533"
}2026-09-11 · trial:NCT05226598
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: efficacy failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "eb509c7b276223992db8e428ccca492cb1f8740c9da3cb5117d16ea948d1baa7",
"metadata": {
"complete": false,
"content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"failed": false,
"last_checked": 1790026980.9308648,
"last_success": 1790026980.9308648,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT05226598"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00
Registry observations (4)
NCT05226598 · TERMINATED · PHASE3 · Metastatic Non-Small Cell Lung Cancer · Trial sponsor Merck Sharp & Dohme LLC
Reported aliases: ABRAXANE®. Identity, treatment role and exposure require review.
NCT04251533 · TERMINATED · PHASE3 · Triple Negative Breast Neoplasms · Trial sponsor Novartis Pharmaceuticals
Reported aliases: abraxane. Identity, treatment role and exposure require review.
NCT05685602 · SUSPENDED · PHASE1 · Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma · Trial sponsor National Cancer Institute (NCI)
Reported aliases: ABI 007; ABI-007; ABI007; Abraxane; Albumin-bound Paclitaxel; Albumin-Stabilized Nanoparticle Paclitaxel; Nanoparticle Albumin-bound Paclitaxel; Nanoparticle Paclitaxel; Naveruclif; Paclitaxel Albumin; paclitaxel albumin-stabilized nanoparticle formulation; Paclitaxel Nanoparticle Albumin-bound; Paclitaxel Protein-Bound; Protein-bound Paclitaxel. Identity, treatment role and exposure require review.
NCT01746225 · COMPLETED · PHASE2 · Metastatic Breastcancer · Trial sponsor ETOP IBCSG Partners Foundation
Reported aliases: Abraxane. Identity, treatment role and exposure require review.